Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
181 participants
INTERVENTIONAL
2021-01-19
2021-08-03
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Preemptive Analgesia Of Dexmedetomidine Reduces Per-operation Pain
NCT06671327
Assessing the Time-Course of Dexmedetomidine-Induced Analgesia Via EEG
NCT06946277
Dexmedetomidine as an Adjuvant for Femoral Nerve Block and Functional Recovery After Total Knee Arthroplasty
NCT04642651
The Effect of Dexmedetomidine Analgesia and Sedation in Minimally Invasive Spine Surgery Under Local Anesthesia
NCT02535273
the Effect of Dexmedetomidine in Coracoid Approach Brachial Plexus Block
NCT02961361
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
HEALTH_SERVICES_RESEARCH
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group 1
Dexmedetomidine group (Group DEX) was given 1.5ug/kg/h Dexmedetomidine continuous infusion Dexmedetomidine group (Group DEX)
Dexmedetomidine
Dexmedetomidine group (Group D) was given 1.5ug/kg/h Dexmedetomidine continuous infusion
Group 2
Midazolam group (Group MID) was continuously pumped with 0.05mg/kg/h midazolam
Midazolam
Midazolam group (Group M) was continuously pumped with 0.05mg/kg/h midazolam
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Dexmedetomidine
Dexmedetomidine group (Group D) was given 1.5ug/kg/h Dexmedetomidine continuous infusion
Midazolam
Midazolam group (Group M) was continuously pumped with 0.05mg/kg/h midazolam
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* American Association of anesthesiologists (ASA) grade Ⅱ \~ IV
* body mass index (BMI) 18.5-40
* planning undergoing peripheral nerve block
Exclusion Criteria
* Alzheimer's disease
* implanted cardiac pacemakers
* mental illness
* epilepsy
* autonomic nervous system diseases
* projected the duration of the operation was more than 3 hours
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
China International Neuroscience Institution
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
China International Neuroscience
Beijing, Beijing Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IRB-XWAD-202008-12
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.